Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare drug provisions of HR 11

Executive Summary

Senate Finance Committee Democratic staffers are urging Clinton transition team to consider legislation at the start of the 103rd Congress to re-introduce the Medicare provisions of HR 11 -- the tax package vetoed by President Bush on Nov. 4. HR 11 proposed to reduce Medicare payments for Amgen's Epogen (recombinant erythropoietin) from $11 to $10 per 1,000 units used in dialysis. HR 11 also would have provided three years of coverage for immunosuppressive drugs for a Medicare transplant patient, versus the current one year. Part B coverage would have been extended to oral cancer drugs.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS021809

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel